Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | phosphoribosylamine--glycine ligase | 0.1152 | 1 | 1 |
Mycobacterium tuberculosis | Probable bifunctional purine biosynthesis protein PurH: phosphoribosylaminoimidazolecarboxamide formyltransferase (AICAR transfo | 0.0574 | 0.4126 | 1 |
Mycobacterium tuberculosis | Probable phosphoribosylformylglycinamidine CYCLO-ligase PurM (AIRS) (phosphoribosyl-aminoimidazole synthetase) (air synthase) | 0.0254 | 0.0875 | 0.2121 |
Mycobacterium ulcerans | bifunctional phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase | 0.0574 | 0.4126 | 0.3562 |
Wolbachia endosymbiont of Brugia malayi | AICAR transformylase/IMP cyclohydrolase PurH | 0.0574 | 0.4126 | 0.3562 |
Onchocerca volvulus | 0.0254 | 0.0875 | 1 | |
Mycobacterium ulcerans | phosphoribosylamine--glycine ligase | 0.1152 | 1 | 1 |
Mycobacterium leprae | Probable bifunctional purine biosynthesis protein PurH : phosphoribosylaminoimidazolecarboxamide formyltransferase (aicar transf | 0.0574 | 0.4126 | 0.3562 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 11 % | Inhibition of human CDK6/cycD1 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 11 % | Inhibition of human CDK6/cycD1 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 13 % | Inhibition of human CDK4/cycD1 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 13 % | Inhibition of human CDK4/cycD1 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 16 % | Inhibition of human VEGFR2 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 16 % | Inhibition of human VEGFR2 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 31 % | Inhibition of human CDK2/cycE expressed in Sf9 cells at 10uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 31 % | Inhibition of human CDK2/cycE expressed in Sf9 cells at 10uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 39 % | Inhibition of mouse PKC alpha expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 39 % | Inhibition of mouse PKC epsilon expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 39 % | Inhibition of mouse PKC alpha expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 39 % | Inhibition of mouse PKC epsilon expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (functional) | = 41 % | Inhibition of vessel growth in chick embryo assay at 25 ug after 24 h | ChEMBL. | 16480264 |
Inhibition (binding) | = 45 % | Inhibition of human TIE2 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 45 % | Inhibition of human TIE2 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 46 % | Inhibition of human CDK4/cycD1 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 46 % | Inhibition of human VEGFR2 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 46 % | Inhibition of human CDK4/cycD1 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 46 % | Inhibition of human VEGFR2 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 47 % | Inhibition of human CDK6/cycD1 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 47 % | Inhibition of human CDK6/cycD1 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 48 % | Inhibition of human CDK1/cycB expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 48 % | Inhibition of human CDK1/cycB expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 65 % | Inhibition of rat PKC gamma expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 65 % | Inhibition of rat PKC gamma expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 66 % | Inhibition of human TIE2 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 66 % | Inhibition of human TIE2 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 67 % | Inhibition of human CDK2/cycE expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 67 % | Inhibition of human CDK2/cycE expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 73 % | Inhibition of human CDK1/cycB expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 73 % | Inhibition of human CDK1/cycB expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 78 % | Inhibition of mouse PKC alpha expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 78 % | Inhibition of human PKC iota expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 78 % | Inhibition of mouse PKC alpha expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 78 % | Inhibition of human PKC iota expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 88 % | Inhibition of human ERBB2 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 88 % | Inhibition of human ERBB2 expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 89 % | Inhibition of human EGFR expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 89 % | Inhibition of human EGFR expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 90 % | Inhibition of human PKC iota expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 90 % | Inhibition of human PKC iota expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 91 % | Inhibition of mouse PKC epsilon expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 91 % | Inhibition of mouse PKC epsilon expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 92 % | Inhibition of human ERBB2 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 92 % | Inhibition of human ERBB2 expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 95 % | Inhibition of human EGFR expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 95 % | Inhibition of human EGFR expressed in Sf9 cells at 10 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 103 % | Inhibition of rat PKC gamma expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Inhibition (binding) | = 103 % | Inhibition of rat PKC gamma expressed in Sf9 cells at 100 uM | ChEMBL. | 16480264 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.